[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
June 16, 2010

Critics Press FDA to Act on Evidence of Rosiglitazone’s Cardiac Safety Issues

JAMA. 2010;303(23):2341-2342. doi:10.1001/jama.2010.788

Controversy over rosiglitazone, a drug used to treat type 2 diabetes that has been linked with sometimes fatal heart-related problems, may be coming to a head as federal regulators are poised to scrutinize evidence about the drug's safety.

Critics of the drug, which is used to lower blood glucose levels, want it removed from the market because meta-analyses and observational studies comparing rosiglitazone with other glucose-controlling drugs have found it is associated with an increased risk of myocardial infarction and cardiovascular death. But others suggest that rosiglitazone should remain a treatment option, at least until results come in from a recently launched randomized controlled trial.

First Page Preview View Large
First page PDF preview
First page PDF preview
×